Acute lung injury
diseaseOn this page
Summary
Acute lung injury (MONDO:0015796) is a disease and 192 clinical trials. Top therapeutic interventions include dexmedetomidine, calfactant, and dobutamine. A subtype of lung disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 21
- Clinical trials: 192
Clinical features
Epidemiology
Prevalence records
4 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | Europe | Validated | |
| Annual incidence | 1-5 / 10 000 | 25 | Europe | Not yet validated |
| Annual incidence | 1-5 / 10 000 | 25 | Australia | Not yet validated |
| Annual incidence | 6-9 / 10 000 | 65 | United States | Not yet validated |
Signs & symptoms
Clinical features (HPO)
21 HPO clinical features (Orphanet curated; top 21 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0002090 | Pneumonia | Frequent (30-79%) |
| HP:0002094 | Dyspnea | Frequent (30-79%) |
| HP:0002098 | Respiratory distress | Frequent (30-79%) |
| HP:0002113 | Pulmonary infiltrates | Frequent (30-79%) |
| HP:0002789 | Tachypnea | Frequent (30-79%) |
| HP:0002878 | Respiratory failure | Frequent (30-79%) |
| HP:0011112 | Abnormality of serum cytokine level | Frequent (30-79%) |
| HP:0011227 | Elevated circulating C-reactive protein concentration | Frequent (30-79%) |
| HP:0012418 | Hypoxemia | Frequent (30-79%) |
| HP:0030783 | Increased circulating interleukin 6 concentration | Frequent (30-79%) |
| HP:0032094 | Increased circulating surfactant protein level | Frequent (30-79%) |
| HP:0000969 | Edema | Occasional (5-29%) |
| HP:0001735 | Acute pancreatitis | Occasional (5-29%) |
| HP:0001945 | Fever | Occasional (5-29%) |
| HP:0002105 | Hemoptysis | Occasional (5-29%) |
| HP:0006530 | Abnormal pulmonary interstitial morphology | Occasional (5-29%) |
| HP:0011118 | Abnormality of tumor necrosis factor secretion | Occasional (5-29%) |
| HP:0025420 | Diffuse alveolar hemorrhage | Occasional (5-29%) |
| HP:0030955 | Alcoholism | Occasional (5-29%) |
| HP:0031273 | Shock | Occasional (5-29%) |
| HP:0100806 | Sepsis | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | acute lung injury |
| Mondo ID | MONDO:0015796 |
| EFO | EFO:0004610 |
| MeSH | D055371 |
| Orphanet | 178320 |
| NCIT | C155766 |
| SNOMED CT | 315345002 |
| MedDRA | 10069351 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of lung disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › acute lung injury
Related subtypes (32): aspiration pneumonia, lung abscess, pneumonic plague, pulmonary alveolar proteinosis, pulmonary systemic sclerosis, obstructive lung disease, bronchiolitis, pulmonary immaturity, rheumatoid arthritis-associated interstitial lung disease, pulmonary embolism and infarction, acute chest syndrome, fungal lung infectious disease, middle lobe syndrome, pulmonary coin lesion, pulmonary plasma cell granuloma, silo filler disease, pulmonary alveolar microlithiasis, pulmonary venoocclusive disease, interstitial lung disease, hantavirus pulmonary syndrome, pulmonary non-tuberculous mycobacterial infection, respiratory failure, lung neoplasm, occupational lung disease, Wilson-Mikity syndrome, neonatal aspiration syndrome, pneumonitis, vanishing lung syndrome, restrictive pulmonary disease, shrinking lung syndrome, dystrophic pulmonary ossification, pulmonary artery disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Heparin | Phase 3 (in late-stage trials) |
| L-Citrulline | Phase 3 (in late-stage trials) |
| Ravulizumab | Phase 3 (in late-stage trials) |
| Sodium Chloride | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Acetylcysteine, Ascorbic Acid, Aspirin, Aviptadil, Calfactant, Dobutamine, Epinephrine, Furosemide, Lactose, Anhydrous, Norepinephrine, Phenylephrine, Pirfenidone, Vasopressin, Voxelotor.
Clinical trials & evidence
Clinical trials
Clinical trials: 192.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 123 |
| PHASE2 | 26 |
| PHASE3 | 9 |
| PHASE1/PHASE2 | 9 |
| PHASE1 | 9 |
| PHASE4 | 7 |
| PHASE2/PHASE3 | 7 |
| EARLY_PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07499154 | PHASE4 | NOT_YET_RECRUITING | Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery |
| NCT00219375 | PHASE4 | COMPLETED | Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan |
| NCT01050699 | PHASE4 | COMPLETED | Sleep Intervention During Acute Lung Injury |
| NCT04133740 | PHASE4 | UNKNOWN | Oxygenation Targets in Cardiac Surgery Patients - a Before-and-after Study |
| NCT04397510 | PHASE4 | TERMINATED | Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury |
| NCT05153525 | PHASE4 | UNKNOWN | Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS |
| NCT05364385 | PHASE4 | UNKNOWN | Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease |
| NCT07342205 | PHASE2/PHASE3 | RECRUITING | A Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation |
| NCT07613099 | PHASE3 | NOT_YET_RECRUITING | Evaluation of Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74 PET/CT Imaging) |
| NCT00133614 | PHASE3 | COMPLETED | Prone Positioning in Pediatric Acute Lung Injury |
| NCT00562835 | PHASE2/PHASE3 | UNKNOWN | Steroids in Patients With Early ARDS |
| NCT00742482 | PHASE3 | TERMINATED | Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy |
| NCT00979121 | PHASE3 | TERMINATED | Statins for Acutely Injured Lungs From Sepsis |
| NCT00999713 | PHASE2/PHASE3 | COMPLETED | CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients |
| NCT01320384 | PHASE2/PHASE3 | COMPLETED | Clinical Effect of the Association of Noninvasive Ventilation and High Flow Nasal Oxygen Therapy in Resuscitation of Patients With Acute Lung Injury (FLORALI Study) |
| NCT01464853 | PHASE3 | TERMINATED | Effect of Enteral Nutrition Support for Critically Ill Patients |
| NCT02891837 | PHASE3 | COMPLETED | L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects |
| NCT04311697 | PHASE2/PHASE3 | COMPLETED | Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure |
| NCT04360096 | PHASE2/PHASE3 | TERMINATED | Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 |
| NCT04369469 | PHASE3 | TERMINATED | Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia |
| NCT04389840 | PHASE2/PHASE3 | TERMINATED | Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure |
| NCT05137795 | PHASE3 | WITHDRAWN | Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 |
| NCT05886998 | PHASE3 | COMPLETED | Nebulized Heparin for Prevention of Acute Lung Injury in Smoke Inhalation Injury |
| NCT05704166 | PHASE2 | RECRUITING | PirfenidoneVsPlacebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following HFRT in Breast Cancer Patients |
| NCT06513949 | PHASE2 | RECRUITING | Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients |
| NCT06853223 | PHASE2 | RECRUITING | This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction |
| NCT00036062 | PHASE1/PHASE2 | COMPLETED | A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury |
| NCT00290602 | PHASE2 | COMPLETED | Early Low Dose Steroid Therapy of Acute Respiratory Distress Syndrome |
| NCT00351533 | PHASE2 | COMPLETED | A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI) |
| NCT00624650 | PHASE2 | COMPLETED | Hemodynamics and Extravascular Lung Water in Acute Lung Injury |
| NCT00655928 | PHASE2 | COMPLETED | Modulation of Lung Injury Complicating Lung Resection |
| NCT00789685 | PHASE1/PHASE2 | COMPLETED | Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II |
| NCT00793013 | PHASE2 | WITHDRAWN | Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation |
| NCT00852605 | PHASE1/PHASE2 | COMPLETED | Acute Lung Injury After Allogeneic Transplantation - Diagnosis and Early Treatment |
| NCT00879606 | PHASE2 | COMPLETED | Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome |
| NCT01274260 | PHASE2 | UNKNOWN | Trial of Steroids in Pediatric Acute Lung Injury/ARDS |
| NCT01326208 | PHASE2 | UNKNOWN | Strategies to Optimize Positive End-expiratory Pressure (PEEP) in Patients With Acute Lung Injury |
| NCT01335932 | PHASE2 | COMPLETED | Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure |
| NCT01339533 | PHASE2 | UNKNOWN | Airway Pressure Release Ventilation (APRV) Versus AC/VC Conventional Ventilation |
| NCT01391481 | PHASE2 | UNKNOWN | Perfluorocarbon (PFC) Inhalation Treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DEXMEDETOMIDINE | 4 | 4 |
| CALFACTANT | 4 | 1 |
| DOBUTAMINE | 4 | 1 |
| ECULIZUMAB | 4 | 1 |
| FENTANYL | 4 | 1 |
| HEPARIN | 4 | 1 |
| ILOPROST | 4 | 1 |
| IMATINIB | 4 | 1 |
| LUCINACTANT | 4 | 1 |
| MARAVIROC | 4 | 1 |
| METHYLPREDNISOLONE SODIUM SUCCINATE | 4 | 1 |
| MIDAZOLAM | 4 | 1 |
| OXYGEN | 4 | 1 |
| PHENYLEPHRINE | 4 | 1 |
| PIRFENIDONE | 4 | 1 |
| RAVULIZUMAB | 4 | 1 |
| SODIUM NITROPRUSSIDE | 4 | 1 |
| VASOPRESSIN | 4 | 1 |
| VOXELOTOR | 4 | 1 |
| XENON | 4 | 1 |
| SIVELESTAT | 3 | 5 |
| DOCIPARSTAT SODIUM | 3 | 1 |
| INTERFERON BETA | 3 | 1 |
| L-CITRULLINE | 3 | 1 |
| LACTOSE, ANHYDROUS | 3 | 1 |
| MEDETOMIDINE | 3 | 1 |
| DAXDILIMAB | 2 | 1 |
| IC14 | 2 | 1 |
| QUISOVALIMAB | 2 | 1 |
| SOLNATIDE | 2 | 1 |
Related Atlas pages
- Drugs: Dexmedetomidine, Calfactant, Dobutamine, Eculizumab, Fentanyl, Heparin, Iloprost, Imatinib, Lucinactant, Maraviroc, Methylprednisolone, Midazolam, Oxygen, Phenylephrine, Pirfenidone, Ravulizumab, Sodium Nitroprusside, Vasopressin, Voxelotor, Xenon, Sivelestat, Dociparstat, Interferon Beta, L-Citrulline, Lactose,, Medetomidine